Hanmi Science Co., Ltd. (KRX:008930)

South Korea flag South Korea · Delayed Price · Currency is KRW
38,350
+3,450 (9.89%)
Mar 5, 2026, 3:30 PM KST
38.20%
Market Cap 2.60T
Revenue (ttm) 1.34T
Net Income (ttm) 75.14B
Shares Out 67.71M
EPS (ttm) 1,110.10
PE Ratio 34.55
Forward PE n/a
Dividend 400.00 (1.15%)
Ex-Dividend Date n/a
Volume 589,003
Average Volume 632,574
Open 37,450
Previous Close 34,900
Day's Range 36,750 - 39,400
52-Week Range 24,250 - 55,500
Beta 0.65
RSI 43.82
Earnings Date Feb 5, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ... [Read more]

Sector Healthcare
Founded 1973
Employees 476
Stock Exchange Korea Stock Exchange
Ticker Symbol 008930
Full Company Profile

Financial Performance

In 2024, Hanmi Science's revenue was 1.28 trillion, an increase of 2.85% compared to the previous year's 1.25 trillion. Earnings were 59.42 billion, a decrease of -48.38%.

Financial Statements

News

Hanmi Science Q4 Operating Profit Rises

(RTTNews) - Hanmi Science (008930.KS) reported fourth quarter net income from continuing operation before income tax of 37.1 billion Korean won compared to a loss of 13.4 billion won, prior year. Net ...

4 weeks ago - Nasdaq